Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia - PubMed (original) (raw)
. 2001 May 1;97(9):2777-83.
doi: 10.1182/blood.v97.9.2777.
Affiliations
- PMID: 11313271
- DOI: 10.1182/blood.v97.9.2777
Free article
Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia
L Granziero et al. Blood. 2001.
Free article
Abstract
In B-cell chronic lymphocytic leukemia (B-CLL), defective apoptosis causes the accumulation of mature CD5(+) B cells in lymphoid organs, bone marrow (BM), and peripheral blood (PB). These cells are the progeny of a proliferating pool that feeds the accumulating compartment. The authors sought to determine which molecular mechanisms govern the proliferating pool, how they relate to apoptosis, and what the role is of the microenvironment. To begin to resolve these problems, the expression and modulation of the family of inhibitor of apoptosis proteins (IAPs) were investigated, with consideration given to the possibility that physiological stimuli, such as CD40 ligand (CD40L), available to B cells in the microenvironment, might modulate IAP expression. The in vitro data on mononuclear cells from PB or BM of 30 patients demonstrate that B-CLL cells on CD40 stimulation express Survivin and that Survivin is the only IAP whose expression is induced by CD40L. Through immunohistochemistry, in vivo Survivin expression in lymph node (LN) and BM biopsies was evaluated. In reactive LN, Survivin was detected only in highly proliferating germinal center cells. In LN from patients with B-CLL, Survivin was detected only in pseudofollicles. Pseudofollicle Survivin(+) cells were actively proliferating and, in contrast to Survivin(+) B cells found in normal GC, were Bcl-2(+). In B-CLL BM biopsies, CD5(+), Survivin(+) cells were observed in clusters interspersed with T cells. These findings establish that Survivin controls the B-CLL proliferative pool interfacing apoptosis and that its expression may be modulated by microenvironmental stimuli.
Similar articles
- Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.
Purroy N, Abrisqueta P, Carabia J, Carpio C, Calpe E, Palacio C, Castellví J, Crespo M, Bosch F. Purroy N, et al. Leukemia. 2014 Oct;28(10):1993-2004. doi: 10.1038/leu.2014.96. Epub 2014 Mar 12. Leukemia. 2014. PMID: 24618734 - Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin.
Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, Peschel C. Decker T, et al. Blood. 2003 Jan 1;101(1):278-85. doi: 10.1182/blood-2002-01-0189. Epub 2002 Aug 29. Blood. 2003. PMID: 12393642 - Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia.
Nakagawa Y, Yamaguchi S, Hasegawa M, Nemoto T, Inoue M, Suzuki K, Hirokawa K, Kitagawa M. Nakagawa Y, et al. Leuk Res. 2004 May;28(5):487-94. doi: 10.1016/j.leukres.2003.10.013. Leuk Res. 2004. PMID: 15068902 - Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.
Hayden RE, Pratt G, Roberts C, Drayson MT, Bunce CM. Hayden RE, et al. Leuk Lymphoma. 2012 Apr;53(4):537-49. doi: 10.3109/10428194.2011.610014. Epub 2011 Sep 23. Leuk Lymphoma. 2012. PMID: 21812539 Review. - CD40 ligand in CLL pathogenesis and therapy.
Schattner EJ. Schattner EJ. Leuk Lymphoma. 2000 May;37(5-6):461-72. doi: 10.3109/10428190009058499. Leuk Lymphoma. 2000. PMID: 11042507 Review.
Cited by
- Clonal relationships of memory B cell subsets in autoimmune mice.
Aranburu A, Engström E, Gerasimcik N, Alsén S, Camponeschi A, Yrlid U, Grimsholm O, Mårtensson IL. Aranburu A, et al. Front Immunol. 2023 Mar 1;14:1129234. doi: 10.3389/fimmu.2023.1129234. eCollection 2023. Front Immunol. 2023. PMID: 36936947 Free PMC article. - The Pt(_S_-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo.
Silconi ZB, Rosic V, Benazic S, Radosavljevic G, Mijajlovic M, Pantic J, Ratkovic ZR, Radic G, Arsenijevic A, Milovanovic M, Arsenijevic N, Milovanovic J. Silconi ZB, et al. Int J Mol Sci. 2022 Jul 24;23(15):8161. doi: 10.3390/ijms23158161. Int J Mol Sci. 2022. PMID: 35897737 Free PMC article. - In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.
Hoferkova E, Kadakova S, Mraz M. Hoferkova E, et al. Cancers (Basel). 2022 Jun 23;14(13):3087. doi: 10.3390/cancers14133087. Cancers (Basel). 2022. PMID: 35804862 Free PMC article. Review. - The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia.
Sun C, Chen YC, Martinez Zurita A, Baptista MJ, Pittaluga S, Liu D, Rosebrock D, Gohil SH, Saba NS, Davies-Hill T, Herman SEM, Getz G, Pirooznia M, Wu CJ, Wiestner A. Sun C, et al. Blood Adv. 2023 Jan 10;7(1):145-158. doi: 10.1182/bloodadvances.2021006941. Blood Adv. 2023. PMID: 35358998 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous